Addiction, Cannabis, Pediatrics / 02.08.2025
RAND Study: Many Young People Don’t Use Less Cannabis to Account for Today’s Higher Potency Products
[caption id="attachment_70143" align="alignleft" width="200"]
Dr. Dunbar[/caption]
MedicalResearch.com Interview with:
Michael S. Dunbar, PhD
Senior Behavioral Scientist
RAND
MedicalResearch.com: What is the background for this study?
Response: Cannabis products are way stronger, or more potent, today than they were 20 years ago. In the past few decades, average levels of THC (i.e., the main substance in cannabis that leads to feeling high) in cannabis products have risen dramatically.
With cannabis becoming increasingly accessible in places like the U.S., health officials have raised questions about how higher-potency products might be associated with problematic cannabis use and related harms, including cannabis use disorder. This is especially important for at-risk groups like young adults, who tend to use cannabis at higher rates than other age groups.
One perspective is that people may use high-potency products less frequently and/or in lower amounts (i.e., “titrate”), which could mitigate some potential risks. Alternatively, if people use higher-potency products more frequently or heavily, it may increase potential for harm. In this study, we looked at how use of higher-potency cannabis flower correlated with use behavior and symptoms of problematic cannabis use in a sample of young adults.
Dr. Dunbar[/caption]
MedicalResearch.com Interview with:
Michael S. Dunbar, PhD
Senior Behavioral Scientist
RAND
MedicalResearch.com: What is the background for this study?
Response: Cannabis products are way stronger, or more potent, today than they were 20 years ago. In the past few decades, average levels of THC (i.e., the main substance in cannabis that leads to feeling high) in cannabis products have risen dramatically.
With cannabis becoming increasingly accessible in places like the U.S., health officials have raised questions about how higher-potency products might be associated with problematic cannabis use and related harms, including cannabis use disorder. This is especially important for at-risk groups like young adults, who tend to use cannabis at higher rates than other age groups.
One perspective is that people may use high-potency products less frequently and/or in lower amounts (i.e., “titrate”), which could mitigate some potential risks. Alternatively, if people use higher-potency products more frequently or heavily, it may increase potential for harm. In this study, we looked at how use of higher-potency cannabis flower correlated with use behavior and symptoms of problematic cannabis use in a sample of young adults.
L. Levi[/caption]
Liran Levi, PhD student
Faculty of Medicine at Hebrew University
MedicalResearch.com: What is the background for this study?
Response: Motivated behavior is driven by a group of brain regions called collectively the reward system. This neural system is at the heart of every decision we make about our actions - it integrates information about the world and decides whether to perform a behavior or not based on the predicted reward/benefit. The key molecule in this process is dopamine - whenever we perform a behavior that provides a reward dopamine is released in the reward system and reinforces this behavior. Drugs of abuse exploit this system - they cause abnormally high levels of dopamine, and thus force the reward system to seek drugs constantly, even after prolonged withdrawal. From a neurobiological perspective, that is how we view substance dependence - the reward system drives people to seek for the reward.
Prof. Ruth Shemer[/caption]
MedicalResearch.com: What types of cells were used in the study, ie keratinocytes, muscle cells etc?
Response: The primary tissue used in this study was peripheral blood from over 300 healthy human donors (18-78 years old). To further understand how the methylation changes are associated with changes in blood cell composition, we also sorted immune cell types including neutrophils, monocytes, B cells, and T cells. For forensics applications, we also tested the clock on urine and saliva samples.
[caption id="attachment_69522" align="alignleft" width="125"]
Prof. Yuval Dor[/caption]
MedicalResearch.com: Does this study relate at all to telomere length?Response:
Response: No, this study does not investigate or reference telomere length. It focuses entirely on DNA methylation changes at few genomics regions, each covering multiple clustered DNA methylation sites, where methylation changes are indicative of chronological age, independently of telomere biology.
MedicalResearch.com: What are the main findings?
Response: - A single-molecule analysis using DNA sequencing, revealed that 
Dr. Campanella[/caption]
Gabriele Campanella, PhD
Assistant Professor
Windreich Department of Artificial Intelligence and Human Health
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study?
Response: Lung cancer is the most lethal cancer in the US. Lung adenocarcinoma (LUAD) is the most common form of lung cancer with an incidence of over 100k per year in the US. EGFR mutations are common driver mutations in LUAD, and importantly, these mutations can be targeted by TKI therapy, which has high response rates. Because of this, EGFR testing via NGS (Next Generation Sequencing) is considered mandatory by guidelines for any LUAD diagnosis.
In high-resource settings, rapid EGFR testing is done while waiting for confirmation via NGS. This is because NGS takes about 2 weeks on average, while the rapid testing has a median TAT of 2 days. Early treatment decisions could be made based on the rapid test results. Rapid tests have some important drawbacks, most notably, it exhausts tissue. In lung cancer, tissue is scarce in the first place, and up to 25% of cases, after rapid testing there is not enough tissue for NGS. In those circumstances, patients have to be biopsied again, which adds unnecessary risk for the patient. Even worse, in some cases, the NGS is never done. A non-tissue-exhaustive computational biomarker could be used instead of the tissue-based rapid test.
